BTIG anlayst Amanda Murphy raised her price target for Crispr Therapeutics to $59 from $51 saying the company's Q2 update confirmed data from CTX001 will be seen in 2019. Beyond CTX110, the company continues to develop additional allogeneic CAR-T product candidates, including CTX120 and CTX130, Murphy tells investors in a research note. The analyst continues to view Crispr's wholly owned allogeneic product pipeline as underappreciated by investors. Murphy expects positive data readouts for CTX001 and CTX110 in 2019 and 2020, respectively, and reiterates a Buy rating on Crispr Therapeutics.